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Introduction: The duration and immunity nature in form of antibodies to COVID-19 is still not clear. But so far 
we know that an immune response protects the individuals from future illness for some specific time. The 
presence or absence of immunity tells us about the future transmission of illness. 
Objectives:  
1. To determine the frequency of antibodies to COVID-19 after three weeks of negative PCR report. 
2. To predict the association of the antibodies values with the severity of the disease the patient had in the 
recent past. 
Material and Methods: We did a cross-sectional study in the department of Pathology on 36 patients recovered 
from COVID-19 from 3rd July 2020 to 31st July 2020. Antibodies level was measured by electro-chemiluminescence 
immunoassay using Roche Cobas E411 Chemistry Analyzer for which commercial kits of Roche diagnostics were 
used as per the instructions of the manufacturer, in respondents after 3 weeks of a negative PCR report. 
Results: The mean with standard deviation for numerical variables i.e. (age and antibodies) was 34+11 years and 
34.52+12.71 respectively. 29(80.55%) were males and 7(19.45%) females.  The mean antibodies level was statically 
significantly higher in patients with age less than 50 years (p-value: 0.01). Patients who had severe symptoms at 
the time of being reported positive by PCR had significantly higher antibody cut-off values as compared to 
asymptomatic positive patients (p-value:0.04). Clinically severe Covid-19 patients positively moderates with an 
increase in the values of the post-infection anti-SARS-COV-2 antibodies supported by an interaction term with 
(β=0.388**; ΔR²=0.126, p-value=0.02). Male gender supported by the results of an interaction term with 
(β=0.388**; ΔR²=0.126, p-value=0.02) had the severe disease as compared to females. 
Conclusion: The higher anti-SARS-COV-2 antibodies were reported in patients with age <50 years and in patients 
who had severe symptoms or a history of hospitalization during the infectious period. There was a statistically 
significant relationship supported by the interactions in terms of higher post-infection antibodies level with the 
male gender, an increase in age and with history of severe disease or hospitalization. 
Keywords: COVID-19, Pandemic, SARS-CoV-2 Antibodies. 
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Introduction 
 
COVID-19 (Coronavirus disease) reportedly originated 
from the wild meat market of a metropolitan city, 
Wuhan, China. It was reported to the World Health 
Organization in Dec 2019. It causes severe respiratory 
disease/pneumonia. It clinically manifests with high-
grade fever, cough, generalized body aches, loss of 
taste and smell and dyspnea.1 By date April 15, 2020, 
globally 19 million people are infected with 
Coronavirus disease (COVID-19) with more than 
120000 deaths from all over the world.2 In Pakistan the 
so far (24th July 2020) reported data from government 
sources to declare 270,400 confirmed cases with 5763 
deaths. 219783 cases are recovered so for and 1316 
cases are under treatment in high dependency units 
countrywide. Sindh is the province with the highest 
number of corona cases crossing 115883.3  
The response to the pandemic was tremendous from 
all over the world focusing mainly on the treatment 
options, vaccination and acquiring the ability for 
serological tests to identify those with immunity to this 
deadly virus.4 That was also the main goal of the 
plasma convalescent therapy approach worldwide 
used to some extent for patient management. The 
dynamics and nature of the immune response to the 
COVID-19 are still limited.5 Antibodies’ testing is done 
to detect immunoglobulins that are produced in 
human blood in response to infection with COVID-19. 
However, the issue is the time period that for how 
long these antibodies are effective to protect an 
individual against the COVID-19. The antibodies 
production is related to the severity of the infection 
and reportedly last for 3 months after the onset of the 
first symptoms.6 Again currently researchers know 
very little about the longevity of these neutralizing 
antibodies to respond, a study suggesting that re-
infection with corona is possible after 80 days in 
patients who developed antibodies against COVID-
19.7 That is worrisome for many scientists expecting a 
second wave of COVID-19 due to re-infection of those 
who were positive by PCR with mild symptoms and 
low levels of neutralizing antibodies.8 The possible 
explanation to how much extent the males are more 
susceptible to acquire infection with more 
consequences is that the number of death reported is 
caused by the gender behaviour (lifestyle) i.e. 
smoking, drinking, and working abroad is more 
among men as compared to women9.  The IgG 
antibodies production in mild, moderate and severe 
COVID differs in gender groups. Antibodies levels in 
the female gender tend to be rise as compared to males 
which may account for a different outcome of 
COVID.10  
The present study was therefore designed to 
determine the frequency of antibodies to COVID-19 
after three weeks of negative PCR report and to 
predict the association of the antibodies values with 
the severity of the disease the patient had in the recent 
past. 
 
Materials and Methods 
 
This cross-sectional study was conducted in the 
Department of Pathology on 36 patients recovered 
from COVID-19 from 3rd July 2020 to 31st July 2020 as 
we have been able to purchase one kit (200 tests) on 
administration, that had an expiry of one month only 
and we have been able to perform more than 150 tests 
out of which 36 were the patients who were reported 
negative on PCR, 3 weeks before. Those patients were 
only picked up from the data and further studied. 
Ethical Approval was taken from the ethical review 
board of Nowshera Medical College Nowshera. Verbal 
consent was taken from all the respondents that their 
confidentiality shall be maintained. 
The criteria for selection of the candidates was that 
only those patients who were reportedly negative on 
PCR for 2019-nCoV done 3 weeks ago, were included 
for their antibodies status. 
All those candidates who came for antibodies test 
without being reported with infection with confirmed 
PCR test for virus detection were excluded. Similarly, 
patients with a duration less than three weeks of being 
reported negative for coronavirus were also excluded 
from the study. 
The procedure was to collect 3ml of the blood in Gel 
tube under aseptic conditions. Antibodies level was 
measured by electro-chemiluminescence immunoassay 
using Roche Cobas E411 Chemistry Analyzer for 
which commercial kits of Roche diagnostics were used 
as per the instructions of the manufacturer, in 
respondents after 3 weeks of a negative PCR report. 
Data was uploaded in the SPSS version 25. Numerical 
variables like age and anti-SARS-COV-2 antibodies 
levels were presented as mean with standard 
deviation and range. 
We applied the Shapiro-wilk test to see the 
distribution of data and with an insignificant p-value, 
we observed a normal distribution of data to develop a 
baseline for further analysis. 
Categorical variables like age categories, gender and 
clinical presentation were presented with percentages. 
An independent t-test was used to determine the 
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difference in mean antibodies level in different 
groups/categories like gender, age categories and 
categories of clinical presentation.  
Linear regression test was used using SPSS version 25 
with the task to predict a positive link of the 
dependent variable, input (antibodies levels, age and 
gender) with the independent variable; output (clinical 
presentation at the time of being reported positive on 
PCR). Interaction terms/values like beta value, 
variation and significance were used to predict the 
relationship of different variables with the severity of 





The mean age of patients with standard deviation was 
34+11 years while mean antibodies cut off values of 
patients with standard deviation was 34.52+12.71. 
(Table 1) 
We included 36 respondents who attended the 
Pathology laboratory of QHAMC for testing their anti-
SARS-COV-2 antibodies after 21 days of being 
negatively reported for 2019 nCoV on PCR. 29 
(80.55%) were females and 7 (19.45%) females. On the 
Shapiro-wilk test to see the distribution of data and 
with an insignificant p-value we observed a normal 
distribution of data to develop a baseline for further 
analysis. (Figure 1)  
A statically significant difference in mean antibody 
cut-off values was noted in age groups of patients. We 
observed that patients with age<50 years had 
developed higher antibodies as compared to patients 
with age>50 years of age (p-value: 0.01). No significant 
difference of antibodies in gender groups was 
observed with insignificant (p-value=0.61). The 
difference in mean post-infection antibodies level was 
statistically significant with higher cut off values in a 
patient who had severe symptoms at the time of being 
reported positive by PCR as compared to an 
asymptomatic patient (p-value=0.04). (Table 2) 
Clinically severe COVID-19 positively moderates with 
an increase in the values of the post-infection anti-
SARS-COV-2 antibodies supported by the results of an 
interaction term with (β=0.388**; ΔR²=0.126, p-
value=0.02). The value of R2, i.e. (R2=0.126), shows that 
exposure (in terms of production of antibodies) is 
accounted for the variability of 12.6% in the cases of 
severe COVID. The p-value which is (p=0.02), 
supported the statistically significant relationship. The 
stated results showed that post-infection antibodies 
cut off values are positively associated with the 
severity of the disease the patient had. One unit 
increment in the antibodies cut off values predicts an 
increment of 3.8% in the rate of the severity of the 
disease the patient had. 
We observed that an increase in age has been shown to 
have a predictive value for severe COVID-19 as 
supported by the linear regression analysis. Beta 
value, i.e., (β=0.064**), showed that there was a 
positive link between an increase in age and severe 
Covid-19.  One unit increment in the age in years will 
cause a 6.4% increment in the rate of the severity of the 
disease. The value of R2, i.e. (R2=0.004), shows that 
exposure is accounted for the variability of 0.4% in the 
cases of severe COVID. The p-value which is 
(p=0.001), supported the statistically significant 
relationship. (Table 3) 
Clinically severe Covid-19 positively moderates with 
gender. Male gender supported by the results of an 
interaction term with (β=0.388**; ΔR²=0.126, p-
value=0.02) had the severe disease as compared to 
females. (Table 3) 
 
Table 1: Descriptive statistics of age and antibodies 
cut off values 
Descriptive 
statistics 
Mean with SD Range 
(Max-Min) 
Age 34+11 (years) 45 (65-20) 
Antibodies 34.52+12.71 126.92 (127-0.08) 
 
Table 2: Mean difference in Anti-SARS-COV-2 antibodies in age and gender groups and based on a clinical 
presentation at the time of positive PCR reporting. (Independent T-Test) 
2.1. Age Categories 




Age<50y 32(88.88%) 35+13 0.01 
Age>50y 4(11.12%) 28+2.8 
Total 36 
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2.2. Gender  




Male 29(80.55%) 34+20 0.61 
Female 7(19.45%) 35+13 
Total 36 
2.3. Clinical presentation 










Table 3: Linear regression analysis to predict severity of Covid-19 against different variables like age, gender, 
post-infection antibodies cut-off values 
Significance at p=0.01**, Significance at p=0.05* 
 




As the pandemic is almost declining in terms of 
severity and mortality in Pakistan, we tried to estimate 
the neutralizing antibodies levels in patients recovered 
from COVID-19 in our teaching hospital. The majority 
of the recovered patients were the health care workers 
of the teaching hospital with a mean and standard 
deviation of the age was  34+11 years while mean 
antibodies cut off values of patients with standard 
deviation was  34.52+12.71. Age factor matters in the 
COVID-19 infection, its severity and mortality. In one 
of our interventions published in the journal of  World 
Family Medicine, we had concluded that a statistically 
significant difference was noted among the age groups 
(p=0.024) .11 Studies from China have reported a high 
rate of the severity of infection with high mortality risk 
Name of predictor B (β-value) ΔR2 (Variability) p-value 
Antibodies value 0.038** 0.126 0.02 
Age 0.064** 0.004 0.001 
Male gender 0.089** 0.024 0.001 
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of 0.48 in an increase in age.12 The antibodies are less 
useful for diagnosis and screening for early infection, 
however, these are helpful to protect the individual 
from re-infection.13 It is a known fact from the so for 
research that a higher antibody title was directly 
associated with a worse clinical classification (p=0.006) 
that was consistent with an understanding that 
patients with severe disease have a higher antibody 
titre in their plasma to neutralize the antigenic virus 
along with high levels of other inflammatory markers 
like d-dimers, ferritin and c reactive proteins.14  
We observed that patients with age<50 years had 
developed higher antibodies as compared to patients 
with age>50 years of age (p-value: 0.01) that indicates 
a high immunity level of the youngster population. In 
another study that we published in Microbes and 
infectious disease (MID), we observed that the rate of 
infectivity and exposure to come across in contacts 
with positive patients with a probability of 2 times 
more than in people with age<55 years (p=0.005, 
OR=2.01) while the case fatality was three times more 
in patients with age >55 years (p=0.001, OR=3.16). The 
mortality rate was 5.41%.15 
No significant difference of antibodies in gender 
groups was observed. However clinically severe 
Covid-19 positively moderates with male gender 
supported by the results of an interaction term with 
(β=0.388**; ΔR²=0.126, p-value=0.02) as compared to 
the female gender. Studies have reported that women 
exhibit greater antibody response as compared to their 
counterparts. Antibodies production is higher in the 
female gender in an early phase of the disease which is 
one of the possible mechanisms that mediates wishful 
recovery in females from COVID-19.16.  
Clinically severe disease moderates with an increase in 
the values of the post-infection anti-SARS-COV-2 
antibodies supported by the interaction terms with 
(β=0.388**; ΔR²=0.126, p-value=0.02). The IgM 
appears after 5-7 days of the initial symptoms and 
disappears in the second week, where the IgG 
antibodies start to appear and reach a peak at 35 days 
after the onset of symptoms and peaking at 4 months 
after the resolution of the infection and then gradually 
decreases but can remain for up to 2 years.17 Studies 
reveal that quantitative detection of antibodies against 
SARS-COV-2 has a strong potential for evaluating the 
severity and prognosis of the disease which shows a 
concordance with our findings.14,18  
Using an independent t-test we observed that patients 
who reportedly had severe symptoms or 
hospitalization history had a higher level of antibodies 
as compared to the patients without symptoms at the 
time of being reported positive for COVID-19 (p=0.04). 
We are aware of the findings of the other researchers 
who reported high levels of IgG in mild and severe 
cases but lowers when the disease enters the critical 
phase (Critical vs mild (p=0.03), critical vs severe 
(p=0.02)).19 The possible explanation would be because 
of high disease activity and low immune response in 
critically ill patients.  
We concluded that the higher anti-SARS-COV-2 
antibodies were reported in patients with age <50 
years and in patients who had severe symptoms or a 
history of hospitalization during the infection period. 
There was a statistically significant relationship 
supported by the interactions in terms of higher post-
infection antibodies level with the male gender, an 
increase in age and history of severe disease or 
hospitalization. 
The study is the first to report the clinical relevance of 
the use of IgG neutralizing antibodies against the 
SARS-COV-2 in our province and probably in the 
country. We covered a small sample that can not be 
sufficient to represent a population, however, it directs 
the researcher to conduct larger population studies to 
see the clinical impact, protective role, correlation of 
these antibodies with the severity of the disease, 




The higher anti-SARS-COV-2 antibodies were reported 
in patients with age <50 years and in patients who had 
severe symptoms or a history of hospitalization during 
the infectious period. There was a statistically 
significant relationship supported by the interactions 
in terms of higher post-infection antibodies level with 
the male gender, an increase in age and with history of 
severe disease or hospitalization. 
     
References 
 
1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. et al. 
Epidemiological and clinical characteristics of 99 cases of 2019 
novel coronavirus pneumonia in Wuhan, China: a descriptive 
study. Lancet. 2020;395:507-13. DOI: 10.1016/S0140-
6736(20)30211-7.  
2. WHO, Coronavirus disease 2019 (COVID-19): Situation 
report—86. https://www.who.int/docs/default-
source/coronaviruse/situation-reports/20200415-sitrep-86-
covid-19.pdf?sfvrsn=c615ea20_6 Date: April 15, 2020, Date 
accessed: April 16, 2020 
3. "Coronavirus in Pakistan - Confirmed Cases". 
www.covid.gov.pk/. Retrieved 24th July 2020. 
4. Godlee F. The burning building. BMJ m1101 (2020). 
DOI:10.1136/bmj.m1101 
14                                                Journal of Rawalpindi Medical College (JRMC); 2021; 25 COVID-19 Supplement-1: 9-14 
5. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H,  et al. 
Detection of SARS-CoV-2-specific humoral and cellular immunity 
in COVID-19 convalescent individuals.  Immunity, 2020; 
52(6):971-977.e3.  DOI: 10.1016/j.immuni.2020.04.023.  
6. Liu A, Wang W, Zhao X, Zhou X, Yang D, Lu M, Lv Y. 
Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 
patient after recovery. Clin Microbiol Infect. 2020, 26(12):1703-
1705. DOI: 10.1016/j.cmi.2020.07.009.  
7. Kellam P., Barclay W. The dynamics of humoral immune 
responses following SARS-CoV-2 infection and the potential for 
reinfection. J Gen Virol, 2020; 101(8):791-97. DOI: 
10.1099/jgv.0.001439.  
8. Kissler SM, Tedijanto C, Goldstein E. Projecting the 
transmission dynamics of SARS-CoV-2 through the postpandemic 
period. Science. 2020;368(6493):860–68. DOI: 
10.1126/science.abb5793. 
9. Bwire GM. Corona virus: Why Men are More Vulnerable to 
Covid-19 than Women? SN Compr Clin Med. 2020; 4:1-3. DOI: 
10.1007/s42399-020-00341-w 
10. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, Hu G, Wang Z, 
Zheng F, Wang L. A comparison study of SARS-CoV-2 IgG 
antibody between male and female COVID-19 patients: A possible 
reason underlying different outcome between sex. J Med 
Virol,2020; 92(10):2050-2054. DOI: 10.1002/jmv.25989.  
11. Khan H. Letter to Editor - Impact of Age Factor in Covid-19 
Infectivity in Population of Nowshera KP, Pakistan. World Family 
Medicine. 2020; 18(5): 75-76. DOI: 
10.5742MEWFM.2020.93813 
12. Li H, Wang S, Zhong F, Bao W, Li Y, Liu L, Wang H, He Y. 
Age-Dependent Risks of Incidence and Mortality of COVID-19 in 
Hubei Province and Other Parts of China. Front Med (Lausanne). 
2020 Apr 30;7:190. DOI: 10.3389/fmed.2020.00190.  
13. Centre for Disease and Radiological Health (CDRH) Report. 
Contains Nonbinding Recommendations This document 
supersedes "Policy for Diagnostics Testing in Laboratories 
Certified to Perform High-Complexity Testing under Clinical 
Laboratory Improvement Amendments (CLIA) prior to Emergency 
Use” issued by U.S. Department of Health and Human Services 
Food and Drug Administration, CDRH, May 4, 2020, Wasington 
USA. 
14.  Li Z., Yi Y., Luo X., Xiong N., Liu Y., Li S. Development and 
clinical Application of A rapid IgM-IgG combined antibody test 
for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 DOI: 
10.1002/jmv.25727.  
15. Khan H, Hussain S, Zar A, Fawad S. Analysis of demographic 
variables in acquiring infection and mortality due to COVID-19. 
Microbes and Infectious Diseases, 2020; 1(2): 70-76. DOI: 
10.21608/mid.2020.34444.1030 
16. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, Hu G, Wang L: A 
comparison study of SARS-CoV-2 IgG antibody between male and 
female COVID-19 patients: a possible reason underlying different 
outcome between gender. J Med Virol, 2020; 92(10):2050-54. 
DOI: 10.1002/jmv.25989.  
17. Lin Q, Zhu L, Ni Z, Meng H, You L. Duration of serum 
neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV 
infection. J Microbiol Immunol Infect, 2020; 53(5):821-22. DOI: 
10.1016/j.jmii.2020.03.015.  
18. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al Clinical 
characteristics of 138 hospitalized patients with 2019 novel 
coronavirus‐infected pneumonia in Wuhan, China. 
JAMA,2020;17;323(11):1061-69. DOI: 
10.1001/jama.2020.1585. 
19. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F et al. 
Detection of IgM and IgG antibodies in patients with coronavirus 
disease 2019. Clin Transl Immunology. 2020 May 
6;9(5):e01136. DOI: 10.1002/cti2.1136.  
